Amended Quarterly Report (10-q/a)
August 08 2016 - 1:35PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q/A
Amendment
No. 1
☒
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:
For
the quarterly period ended June 30, 2016
☐
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:
For
the transition period from ___________ to ___________.
Commission
File Number 0-32201
BIO-MATRIX
SCIENTIFIC GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
|
DELAWARE
|
33-0824714
|
(State
of Incorporation)
|
(I.R.S.
Employer Identification No.)
|
|
|
4700
Spring Street, Suite 304, La Mesa, California
|
91942
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(619)
702-1404
(Registrant's
telephone number, including area code)
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes
☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes
☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated
filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
☐
Large accelerated filer
|
☐
Accelerated filer
|
☐
Non-accelerated filer
|
☒
Smaller reporting company
|
Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934) (check
one):
Yes
☒ No ☐
There
were 5,746,386,628 shares of Common Stock outstanding as of June 30, 2016.
EXPLANATORY NOTE
The
purpose of this amendment on Form 10-Q/A to Bio-Matrix Scientific Group, Inc's Quarterly Report on Form 10-Q for the period
ended June 30, 2016, filed with the Securities and Exchange Commission on August 8, 2016 is solely to furnish
Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.
No
other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the
Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update
in any way disclosures made in the original Form 10-Q.
Item
6. EXHIBITS
**31.1
|
Certification
of Chief Executive Officer
|
**31.2
|
Certification
of Acting Chief Financial Officer
|
**32.1
|
Certification
of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
|
**32.2
|
Certification
of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
|
**10.1
|
Form
of $50,000 Convertible Note
|
**10.2
|
Form
of $50,000 Unit Purchase Agreement dated June 1, 2016
|
**10.3
|
Form
of $50,000 Unit Purchase Agreement dated May 16 2016
|
**10.4
|
Form
of $54, 750 Unit Purchase Agreement
|
**10.5
|
Form
of $25,000 Unit Purchase Agreement
|
**10.6
|
Form
of $150,000 Unit Purchase Agreement
|
**10.7
|
Agreement
with BA Securities/Objective Capital (a)
|
**10.8
|
Agreement
with CIM Securities (b)
|
|
|
*101.INS
|
XBRL
Instance Document
|
*101.SCH
|
XBRL
Taxonomy Extension Schema
|
*101.CAL
|
XBRL
Taxonomy Extension Calculation Linkbase
|
*101.DEF
|
XBRL
Taxonomy Extension Definition Linkbase
|
*101.LAB
|
XBRL
Taxonomy Extension Label Linkbase
|
*101.PRE
|
XBRL
Taxonomy Extension Presentation Linkbase
|
*
Furnished herewirth
**
Previously filed
|
(a)
|
Incorporated
by Reference to Exhibit 10.1 of that Form 8-K filed by the Company dated June 8, 2016
|
|
(b)
|
Incorporated
by reference Exhibit 10.1 of that Form 8-K filed by the Company dated July 7, 2016
|
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Bio-Matrix
Scientific Group, Inc.
|
|
|
|
|
By:
|
/s/
David R. Koos
|
|
Name:
|
David
R. Koos
|
|
Title:
|
Principal
Executive Officer
|
|
Date:
|
August
8, 2016
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf
of the Registrant and in the capacities indicated on August 8, 2016.
|
|
Bio-Matrix
Scientific Group, Inc.
|
|
|
|
|
By:
|
/s/
David R. Koos
|
|
Name:
|
David
R. Koos
|
|
Title:
|
Sole
Director
|
|
Date:
|
August
8, 2016
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf
of the Registrant and in the capacities indicated on August 8, 2016.
|
|
Bio-Matrix
Scientific Group, Inc.
|
|
|
|
|
By:
|
/s/
David R. Koos
|
|
Name:
|
David
R. Koos
|
|
Title:
|
Principal
Financial Officer
|
|
Date:
|
August
8, 2016
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf
of the Registrant and in the capacities indicated on August 8, 2016.
|
|
Bio-Matrix
Scientific Group, Inc.
|
|
|
|
|
By:
|
/s/
David R. Koos
|
|
Name:
|
David
R. Koos
|
|
Title:
|
Principal
Accounting Officer
|
|
Date:
|
August
8, 2016
|